Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.70
EXEL's Cash to Debt is ranked higher than
54% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. EXEL: 0.70 )
EXEL' s 10-Year Cash to Debt Range
Min: 0.52   Max: No Debt
Current: 0.7

Equity to Asset 0.13
EXEL's Equity to Asset is ranked higher than
50% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. EXEL: 0.13 )
EXEL' s 10-Year Equity to Asset Range
Min: -3.9   Max: 0.79
Current: 0.13

-3.9
0.79
F-Score: 2
Z-Score: -4.68
M-Score: -2.42
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -640.54
EXEL's Operating margin (%) is ranked higher than
56% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -66.98 vs. EXEL: -640.54 )
EXEL' s 10-Year Operating margin (%) Range
Min: -673.24   Max: 30.91
Current: -640.54

-673.24
30.91
Net-margin (%) -781.03
EXEL's Net-margin (%) is ranked higher than
55% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -56.37 vs. EXEL: -781.03 )
EXEL' s 10-Year Net-margin (%) Range
Min: -781.03   Max: 26.14
Current: -781.03

-781.03
26.14
ROE (%) -369.52
EXEL's ROE (%) is ranked lower than
52% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: -21.87 vs. EXEL: -369.52 )
EXEL' s 10-Year ROE (%) Range
Min: -369.52   Max: 83.52
Current: -369.52

-369.52
83.52
ROA (%) -48.63
EXEL's ROA (%) is ranked higher than
60% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: -18.90 vs. EXEL: -48.63 )
EXEL' s 10-Year ROA (%) Range
Min: -174.43   Max: 19.25
Current: -48.63

-174.43
19.25
ROC (Joel Greenblatt) (%) -4088.23
EXEL's ROC (Joel Greenblatt) (%) is ranked higher than
54% of the 872 Companies
in the Global Biotechnology industry.

( Industry Median: -196.35 vs. EXEL: -4088.23 )
EXEL' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -4088.23   Max: 1052.61
Current: -4088.23

-4088.23
1052.61
Revenue Growth (%) -53.70
EXEL's Revenue Growth (%) is ranked higher than
56% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: -1.30 vs. EXEL: -53.70 )
EXEL' s 10-Year Revenue Growth (%) Range
Min: -53.7   Max: 25.6
Current: -53.7

-53.7
25.6
EBITDA Growth (%) 16.90
EXEL's EBITDA Growth (%) is ranked higher than
91% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -10.30 vs. EXEL: 16.90 )
EXEL' s 10-Year EBITDA Growth (%) Range
Min: -44.8   Max: 17.8
Current: 16.9

-44.8
17.8
EPS Growth (%) 16.10
EXEL's EPS Growth (%) is ranked higher than
91% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: -12.80 vs. EXEL: 16.10 )
EXEL' s 10-Year EPS Growth (%) Range
Min: -42.1   Max: 16.1
Current: 16.1

-42.1
16.1
» EXEL's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

EXEL Guru Trades in Q1 2013

Jean-Marie Eveillard 1,175,800 sh (unchged)
Paul Tudor Jones Sold Out
Steven Cohen Sold Out
John Burbank Sold Out
» More
Q2 2013

EXEL Guru Trades in Q2 2013

Jean-Marie Eveillard 1,073,300 sh (-8.72%)
» More
Q3 2013

EXEL Guru Trades in Q3 2013

Jean-Marie Eveillard 1,173,300 sh (+9.32%)
» More
Q4 2013

EXEL Guru Trades in Q4 2013

Steven Cohen 14,300 sh (New)
Jean-Marie Eveillard 1,173,300 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with EXEL

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Burbank 2013-03-31 Sold Out 0.0019%$4.41 - $5.03 $ 3.32-29%0
John Burbank 2012-12-31 New Buy$4.33 - $5.32 $ 3.32-31%10753
Jean-Marie Eveillard 2012-09-30 Add 422.58%0.02%$4.28 - $6.45 $ 3.32-37%1175800
Jean-Marie Eveillard 2012-03-31 Add 125%$4.49 - $6.47 $ 3.32-35%225000
Jean-Marie Eveillard 2011-12-31 New Buy$3.95 - $7.81 $ 3.32-34%100000
Carl Icahn 2011-09-30 Sold Out 0.43%$5.5 - $9.22 $ 3.32-55%0
Jean-Marie Eveillard 2011-03-31 Sold Out $7.22 - $12.45 $ 3.32-66%0
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 9.40
EXEL's P/B is ranked lower than
58% of the 791 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. EXEL: 9.40 )
EXEL' s 10-Year P/B Range
Min: 1.84   Max: 1113
Current: 9.4

1.84
1113
P/S 19.50
EXEL's P/S is ranked lower than
64% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 10.27 vs. EXEL: 19.50 )
EXEL' s 10-Year P/S Range
Min: 1.65   Max: 50.5
Current: 19.5

1.65
50.5
EV-to-EBIT 7.20
EXEL's EV-to-EBIT is ranked higher than
84% of the 468 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. EXEL: 7.20 )
EXEL' s 10-Year EV-to-EBIT Range
Min: 6.1   Max: 41.3
Current: 7.2

6.1
41.3

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 332.00
EXEL's Price/Tangible Book is ranked lower than
93% of the 736 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. EXEL: 332.00 )
EXEL' s 10-Year Price/Tangible Book Range
Min: 3.6   Max: 613
Current: 332

3.6
613
Price/Median PS Value 2.70
EXEL's Price/Median PS Value is ranked lower than
65% of the 725 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. EXEL: 2.70 )
EXEL' s 10-Year Price/Median PS Value Range
Min: 0.27   Max: 4.9
Current: 2.7

0.27
4.9
Earnings Yield (Greenblatt) 13.90
EXEL's Earnings Yield (Greenblatt) is ranked higher than
81% of the 378 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. EXEL: 13.90 )
EXEL' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2.4   Max: 16.4
Current: 13.9

2.4
16.4
Forward Rate of Return (Yacktman) -16.42
EXEL's Forward Rate of Return (Yacktman) is ranked higher than
72% of the 669 Companies
in the Global Biotechnology industry.

( Industry Median: -9.87 vs. EXEL: -16.42 )
EXEL' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -16.4   Max: -7.7
Current: -16.42

-16.4
-7.7

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:EX9.Germany
Exelixis, Inc. formerly known as Exelixis Pharmaceuticals, Inc was incorporated in Delaware in November 1994. It is a biotechnology company that develops innovative therapies for cancer and other serious diseases and through its integrated drug discovery and development activities is building a portfolio of novel compounds that has the potential to be high-quality, differentiated pharmaceutical products that could make a meaningful difference in the lives of patients. The majority of programs focus on discovery and development of small molecule drugs for cancer. L184, It's most advanced drug candidate, inhibits MET, VEGFR2 and RET, proteins that are key drivers of tumor growth and/or vascularization. XL184 is the advanced inhibitor of MET in clinical development and is being evaluated in the development program in collaboration with Bristol-Myers Squibb Company. The Company is currently conducting majority of the development activity for XL184, and its collaboration agreement provides for the sharing of development costs. A global phase 3 registration trial of XL184 as a potential treatment for medullary thyroid cancer is currently enrolling. The established collaborations with pharmaceutical and biotechnology companies, including Bristol-Myers Squibb, sanofi-aventis, Genentech, Boehringer Ingelheim GmbH and GlaxoSmithKline that allows retaining economic participation in compounds and supporting additional development of its pipeline. The Company's collaborations generally fall into one of two categories: collaborations in which it co-develop compounds with a partner, share development costs and profits from Its potential competitors include major pharmaceutical and biotechnology companies, as well as academic research institutions, clinical reference laboratories and government agencies.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide